Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12098835 | 1.00 | GBA1 (0.46) | GBA1SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL7805384 | 0.83 | HTR3A (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4436017 | 0.83 | TAAR1 (0.44) | TAAR1 | |
| SCHEMBL11821505 | 0.82 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL4161319 | 0.79 | MLNR (0.36) | — | |
| SCHEMBL9111411 | 0.79 | CYP19A1 (0.43) | TAAR1 | |
| SCHEMBL2091317 | 0.77 | GBA1 (0.53) | GBA1SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL2204874 | 0.77 | SLC6A4 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6985506 | 0.77 | MEN1 (0.36) | TAAR1 | |
| SCHEMBL4839660 | 0.77 | REN (0.43) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117298148-A | Application of aminodithioformate compound or pharmaceutically acceptable salt thereof in combination with copper ions in preparation of antitumor drugs | 北京大学 | 2023-12-29 | — | — | CN | claimed |
| WO-2023001268-A1 | CHRYSIN DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳枫语生物医药科技有限公司 | 2023-01-26 | — | — | WO | claimed |
| US-20220112187-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-04-14 | — | — | US | claimed |
| CN-113773293-A | Chrysin derivative and preparation method thereof | 深圳枫语生物医药科技有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-113768915-A | Application of chrysin derivative in preparation of medicine | 深圳枫语生物医药科技有限公司 | 2021-12-10 | — | — | CN | claimed |
| EP-3849974-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-21 | — | — | EP | claimed |
| CN-112673007-A | Pyrazolopyridine amine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-04-16 | — | — | CN | claimed |
| CN-110156752-B | 2- [ (pyridine-2-ylmethyl) sulfenyl ] -1H-benzimidazole compound and application thereof | 沈阳药科大学 | 2021-03-19 | — | — | CN | claimed |
| CN-108586335-B | 2-hydroxybenzamide-1, 2,3, 4-tetrahydroisoquinoline-O-carbamate compound and preparation method thereof | 南阳师范学院 | 2020-07-03 | — | — | CN | claimed |
| WO-2020052738-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | claimed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | claimed |
| WO-1992003131-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES | G.D. SEARLE & CO. (US) | 1992-03-05 | — | — | WO | claimed |
| US-4808609-A | Amino-(hydroxy)alkoxy-4-phenylpropyl indoles having antiarrythmic activity | ROUSSEL UCLAF (FR) | 1989-02-28 | — | — | US | claimed |
| US-4801590-A | ANGINA, ANTICANCER, CARDIOVASCULAR DISORDERS, HEADACHES, PSORIASIS, ASTHMA, ANTICOAGULANTS | BEIERSDORF AG (DE) | 1989-01-31 | — | — | US | claimed |
| EP-0099802-B1 | THIENO(3,2-C) PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | ELF SANOFI (FR) | 1987-02-04 | — | — | EP | claimed |
| EP-0054974-B1 | IMIDAZOLYLPROPANOL COMPOUNDS AND THEIR ACID ADDITION SALTS, AND PRODUCTION AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-07-10 | — | — | EP | claimed |
| EP-0006227-B1 | ANTITHROMBOTIC PHARMACEUTICAL PREPARATION CONTAINING 2,2'-DITHIOBIS BENZAMIDE DERIVATIVES AND NEW 2,2'-DITHIOBIS BENZAMIDE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD (JP) | 1984-12-27 | — | — | EP | claimed |
| EP-0080721-A2 | Diphenylalkanoamine derivatives, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-06-08 | — | — | EP | claimed |
| EP-0002066-B1 | 2-ADAMANTYL HYDRAZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Teva Pharmaceutical Industries Limited (IL) | 1983-05-25 | — | — | EP | claimed |
| US-4016263-A | BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112187-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, KCNJ1, KCNJ11 | GBA1 758/4885SLC6A2 1758/4885SLC6A4 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.